VERDI: Video Education With Result Dependent dIsclosure

Sponsor
Dana-Farber Cancer Institute (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05225428
Collaborator
National Cancer Institute (NCI) (NIH), National Human Genome Research Institute (NHGRI) (NIH)
1,020
1
3
49
20.8

Study Details

Study Description

Brief Summary

The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better serve a more diverse patient population at risk for hereditary cancers.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Video Education
  • Behavioral: Genetic Counseling
N/A

Detailed Description

This study consists of two parts:
  • Qualitative assessment:

  • This part of the research study involves watching a brief educational video about genetic testing for inherited cancer risk (about 8 minutes) before completing a short interview by video or telephone with trained researchers. This interview will be digitally recorded for later review. Participation in the study will be considered complete after the interview is finished. The qualitative assessment study will recruit 20 total participants.

  • The data gathered from this study will inform the refinement and adaptation of the VERDI model for the subsequent randomized controlled trial.

  • Randomized control trial:

  • A randomized controlled trial (RCT) will evaluate the VERDI model vs. standard genetic counseling in 1000 participants

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1020 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Video Education With Result Dependent dIsclosure
Anticipated Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
Sep 1, 2025
Anticipated Study Completion Date :
Sep 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: QUALITATIVE ASSESSMENT

This part of the research study involves watching a brief educational video about genetic testing for inherited cancer risk (about 8 minutes) before completing a short interview by video or telephone with trained researchers. This interview will be digitally recorded for later review. It is expected that about 20 people will take part in this part of the research study. In the larger part of the study that will happen after this part of the study, it is expected 1000 people will participate.

Behavioral: Video Education
Investigator-developed, professionally animated and produced 8-minute video (Video Education) summarizing the core educational components of a genetic counseling visit
Other Names:
  • VERDI
  • Experimental: RCT-VERDI

    A randomized controlled trial (RCT) will evaluate the VERDI model vs. standard genetic counseling

    Behavioral: Video Education
    Investigator-developed, professionally animated and produced 8-minute video (Video Education) summarizing the core educational components of a genetic counseling visit
    Other Names:
  • VERDI
  • Experimental: RCT-Genetic Counseling

    A randomized controlled trial (RCT) will evaluate the VERDI model vs. standard genetic counseling

    Behavioral: Genetic Counseling
    Standard genetic counseling

    Outcome Measures

    Primary Outcome Measures

    1. Video Education Acceptability (Qualitative Interview Study) [3 Weeks]

      Pre- and post-test of knowledge of hereditary cancer risk and cancer genetic counseling with qualitative patient interview question domains and instruments to assess understanding of language and imagery of video education as correlated with measures of health literacy.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age ≥ 18 years

    • Current or prior diagnosis of breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, colorectal cancer, renal cancer, melanoma, or sarcoma

    • Ability to understand spoken or written English or Spanish in a healthcare context

    • Ability to understand and the willingness to sign a written informed consent document

    • Black or Latinx (qualitative assessment study only)

    Exclusion Criteria:
    • Prior cancer genetic testing

    • Prior germline genetic testing

    • Active hematologic malignancy (e.g. chronic lymphocytic leukemia)

    • Currently pregnant

    • Currently incarcerated

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Dana Farber Cancer Institute Boston Massachusetts United States 02115

    Sponsors and Collaborators

    • Dana-Farber Cancer Institute
    • National Cancer Institute (NCI)
    • National Human Genome Research Institute (NHGRI)

    Investigators

    • Principal Investigator: Huma Q. Rana, MD., MPH, Dana-Farber Cancer Institute

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Huma Rana, Principal Investigator, Dana-Farber Cancer Institute
    ClinicalTrials.gov Identifier:
    NCT05225428
    Other Study ID Numbers:
    • 21-508
    • R01HG011928
    First Posted:
    Feb 4, 2022
    Last Update Posted:
    Aug 18, 2022
    Last Verified:
    Aug 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Huma Rana, Principal Investigator, Dana-Farber Cancer Institute
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 18, 2022